

=> fil hcaplu

FILE 'HCAPLUS' ENTERED AT 17:02:33 ON 25 MAR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Mar 2003 VOL 138 ISS 13  
FILE LAST UPDATED: 24 Mar 2003 (20030324/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d stat que

L1 1 SEA FILE=REGISTRY IMMUNOFERON/CN  
L2 2 SEA FILE=REGISTRY ("NIGELLA SATIVA, EXT." /CN OR "NIGELLIC ACID" /CN)  
L3 2 SEA FILE=HCAPLUS IMMUNOFERON OR L1  
L4 2 SEA FILE=HCAPLUS GLYCOPHOSPHOPEPTICAL?  
L6 269 SEA FILE=HCAPLUS L2 OR NIGELLA(W) SATIVA  
L7 4 SEA FILE=HCAPLUS (L3 OR L4 OR L6) AND (?ASTHMA? OR ?ALLERG? OR ?RHINIT? OR CONJUNCTIV? OR URTICARIA OR ATOPIC(W) DERMAT? OR LARYNG? OR OEDEMA?)

=> d ibib abs hitrn 17 1-4

L7 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:716877 HCAPLUS  
DOCUMENT NUMBER: 137:237775  
TITLE: Sterol fractions of *Nigella sativa*  
L. seeds  
INVENTOR(S): Kandil, Osama  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 11 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002132019	A1	20020919	US 2001-29886	20011231
PRIORITY APPLN. INFO.:			US 2000-258555P	P 20001229

AB The present invention provides novel compns. comprising a *N. sativa* sterol fraction. The present invention also provides novel compns. comprising .beta.-sitosterol, campesterol, .beta.-amyirin, stigmasterol, or any

combination thereof. The present invention provides novel methods for treating and preventing fungal infections, bacterial infections, and vaginal diseases and disorders by administering the novel compns. of the invention. The present invention also provides methods for treating or preventing inflammation, pain and/or allergic reactions by administering the novel compns. of the invention. A pharmaceutical formulation was prepd. contg. 10% of the N. sativa sterol fraction as a vaginal suppository contg. 0.4 g N. sativa sterol fraction in a base of 3.6 g PEG. The mixt. was poured into a vaginal suppository mold, allowed to cool, cleaned and dispensed. Exptl. and clin. trials confirmed that the above vaginal suppositories were a potent and safe formulation that successfully treated vaginal moniliasis.

L7 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:627968 HCAPLUS

DOCUMENT NUMBER: 133:202992

TITLE: **Glycophosphopeptical or Nigella sativa seeds for asthma/allergy therapy that targets T-lymphocytes and/or eosinophils**

INVENTOR(S): Nassief, Nida Abdul-Ghani

PATENT ASSIGNEE(S): Al-Jassim, Rawaa, Australia; Al-Kaisi, Ban; James, David

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051580	A2	20000908	WO 2000-IB222	20000302
WO 2000051580	A3	20011018		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2348132	A1	20000927	GB 2000-5003	20000301
EP 1242102	A2	20020925	EP 2000-909548	20000302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2002061841	A1	20020523	US 2001-944564	20010904
PRIORITY APPLN. INFO.:				
			GB 1999-4777	A 19990302
			GB 1999-13341	A 19990608
			WO 2000-IB222	W 20000302

AB A pharmaceutical compn. for the treatment and/or prophylaxis of diseases caused by type I hypersensitivity reactions consisting essentially of **glycophosphopeptical, or pure Nigella Sativa** seeds, in a concn. which stimulate Th1 lymphocytes and selectively switch-off the eosinophilic airway inflammation. A method of treatment of **allergy** using Th1 stimulating agents, to be administered to a mammal such as human in need of such treatment in a shot of 5 days only, resulted in significant decrease in symptom score started day 3, and in

sputum eosinophils by day 14, followed by long-term clin. remission of a mean of 6 mo. The BCG-like Th1 stimulation is also used in treating diseases in which the body defensive mechanism is a cell-mediated immunity, including viral infections, including influenza and common cold, chronic and recurrent urinary tract infection, pelvic inflammatory diseases as neuroimmune appendicitis, cancer, Crohn's disease and facial palsy.

L7 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1966:22185 HCAPLUS  
DOCUMENT NUMBER: 64:22185  
ORIGINAL REFERENCE NO.: 64:4118f-g  
TITLE: Egyptian *Nigella sativa*  
AUTHOR(S): El-Dakhakhny, M.  
CORPORATE SOURCE: Univ. Alexandria, Egypt  
SOURCE: Arzneimittelforsch. (1965), 15(10), 1227-9  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The L.D.50 values of thymoquinone (isolated from *N. sativa*) thymohydroquinone, and polythymoquinone were 10, 25, and 150 mg./kg., resp., in rats. All 3 compds. at 4 mg./kg. body wt. showed uricosuric activity in rats and choleretic activity in dogs and protected guinea pigs from the bronchospasm induced by exposure to a mist of histamine, although varying degrees of toxicity were shown by the 3 compds. in each test. Polythymoquinone was the least active compd., yet because of its lower toxicity it may be therapeutically useful in patients with hepatic insufficiency, gout, arthritis, and some cases of bronchial **asthma**

L7 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1963:22728 HCAPLUS  
DOCUMENT NUMBER: 58:22728  
ORIGINAL REFERENCE NO.: 58:3790c-e  
TITLE: Chemical and pharmacological properties of the new anti-**asthmatic** drug, nigellone  
AUTHOR(S): Mahfouz, M.; El-Dakhakhny, M.  
CORPORATE SOURCE: Univ. Alexandria, Egypt  
SOURCE: Egypt. Pharm. Bull. (1960), 42(No. 4), 411-24  
DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable

AB The new compd. nigellone (I) from the essential oil of *Nigella sativa* (CA 56, 6091g) was further investigated. The formation of a semicarbazone and a 2,4-dinitrophenyl-hydrazone showed a carbonyl group. The formation of a dicarbazone demonstrated the presence of 2 carbonyl groups in I. The ultraviolet absorption curve of I and 2 of its derivs. in EtOH are shown. The infrared absorption spectrum of I (shown) also indicated a carbonyl structure as well as the absence of OH and COOH groups. I gave a pink soln. in NaOH soln. and was sol. in several org. solvents particularly CHCl<sub>3</sub>, but was nearly insol. in water. The I mol. seemed to show conjugated unsatn. Its soly. in alk. solns. was attributed to enolization. The most marked pharmacol. property of I was its ability to protect guinea pigs against bronchospasms induced by inhaling sprays contg. histamine (II). However, I did not antagonize II-induced contractions in isolated tracheas of guinea pigs. Since the protective action of I in intact animals did not occur unless I was injected intramuscularly 2-3 hrs. before contact with the II spray, it is probable that I was converted in the body into some active compd. Other tests indicated that I possibly had a direct action on bronchial muscles and did not act through the nerve connections. Tests of the action of I against

II in guinea pig ileum and uterus are described. I had little effect on circulation in isolated toad or mammalian hearts and did not affect blood pressure in dogs or cats. Human pharmacotherapeutic trials indicated that I controlled some cases of bronchial **asthma**. Since I antagonized the production of contractions induced by pituitrin (III) in rat, rabbit, or pig uterus, the pharmacol. use of I should be avoided in cases where a full action of III is desired.

show files

File 155:MEDLINE(R) 1966-2003/Mar W3  
 (c) format only 2003 The Dialog Corp.  
 File 5:Biosis Previews(R) 1969-2003/Mar W3  
 (c) 2003 BIOSIS  
 File 34:SciSearch(R) Cited Ref Sci 1990-2003/Mar W3  
 (c) 2003 Inst for Sci Info  
 File 35:Dissertation Abs Online 1861-2003/Feb  
 (c) 2003 ProQuest Info&Learning  
 File 65:Inside Conferences 1993-2003/Mar W3  
 (c) 2003 BLDSC all rts. reserv.  
 File 71:ELSEVIER BIOBASE 1994-2003/Mar W4  
 (c) 2003 Elsevier Science B.V.  
 File 73:EMBASE 1974-2003/Mar W3  
 (c) 2003 Elsevier Science B.V.  
 File 94:JICST-EPlus 1985-2003/Mar W4  
 (c) 2003 Japan Science and Tech Corp(JST)  
 File 144:Pascal 1973-2003/Mar W3  
 (c) 2003 INIST/CNRS  
 File 165:EventLine(TM) 1990-2003/Mar  
 (c) 2003 Elsevier Science B.V.  
 File 340:CLAIMS(R)/US Patent 1950-03/Mar 20  
 (c) 2003 IFI/CLAIMS(R)  
 File 345:Inpadoc/Fam. & Legal Stat 1968-2003/UD=200311  
 (c) 2003 EPO  
 File 351:Derwent WPI 1963-2003/UD,UM &UP=200318  
 (c) 2003 Thomson Derwent  
 File 357:Derwent Biotech Res. 1982-2003/Mar W3  
 (c) 2003 Thomson Derwent & ISI  
 File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec  
 (c) 1998 Inst for Sci Info  
 File 440:Current Contents Search(R) 1990-2003/Mar 25  
 (c) 2003 Inst for Sci Info

?ds

Set	Items	Description
S1	4	GLYCOPHOSHOPEPTIC? AND (ASTHMA OR ALLERG? OR RHINIT? OR C- ONJUNCT? OR URTICARIA OR DERMAT? OR OEDEMA or respir?)
S2	3	RD (unique items)

?t2/3 ab/1-3  
 >>>No matching display code(s) found in file(s): 65, 165, 345

2/AB/1 (Item 1 from file: 340)  
 DIALOG(R)File 340:CLAIMS(R)/US Patent  
 (c) 2003 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 10118234 IFI Acc No: 2002-0061841 IFI Acc No: 2002-0016917  
 Document Type: C  
 ASTHMA / ALLERGY THERAPY THAT TARGETS T-LYMPHOCYTES AND/OR EOSINOPHILS;  
 USE OF GLYCOPHOSHOPEPTICAL FOR THE TREATMENT AND/OR PROPHYLAXIS OF  
 ALLERGY / ASTHMA  
 Inventors: Nassief Nida Abdul-Ghani (IQ)  
 Assignee: Unassigned Or Assigned To Individual  
 Assignee Code: 68000  
 Publication (No,Date), Applic (No,Date):  
 US 20020061841 20020523 US 2001944564 20010904  
 Publication Kind: A1  
 Priority Applic(No,Date): GB 9947771 19990302

Abstract: A pharmaceutical composition for the treatment and/or prophylaxis of diseases caused by type I hypersensitivity reactions consisting essentially of Glicophosphopeptical, or pure Nigella Sativa seeds, in a

concentration which stimulate Th1 lymphocytes and selectively switch-off the eosinophilic airway inflammation A method of treatment of allergy using Th1 stimulating agents, to be administered to a mammal such as human in need of such treatment in a shot of 5 days only, resulted in significant decrease in symptom score started day 3, and in sputum eosinophils by day 14, followed by long-term clinical remission of a mean of 6 months. The BCG-like Th1 stimulation is also used in treating diseases in which the body defensive mechanism is a Cell Mediated Immunity, including viral infections, as but not limited to influenza and common cold, Chronic and recurrent urinary tract infection, pelvic inflammatory diseases as neuroimmune appendicitis, cancer, crohns disease and facial palsy.

2/AB/2 (Item 1 from file: 345)  
 DIALOG(R)File 345:Inpadoc/Fam.& Legal Stat  
 (c) 2003 EPO. All rts. reserv.

15179448

Basic Patent (No,Kind,Date): GB 9904777 A0 19990428 <No. of Patents: 011>  
 NOVEL METHOD, AN ASTHMA THERAPY THAT ACT ON EOSINOPHILS AND/OR  
 T-LYMPHOCYTES (English)

Patent Assignee: NASSIEF NIDA A

Language of Document: English

Patent Family:

Patent No	Kind	Date	Applic No	Kind	Date
AU 200031829	A5	20000921	AU 200031829	A	20000302
EP 1242102	A2	20020925	EP 2000909548	A	20000302
GB 9904777	A0	19990428	GB 994777	A	19990302 (BASIC)
GB 9908034	A0	19990602	GB 998034	A	19990408
GB 9913341	A0	19990811	GB 9913341	A	19990608
GB 200003115	A0	20000405	GB 203115	A	20000208
GB 200005003	A0	20000419	GB 20005003	A	20000301
GB 2348132	A1	20000927	GB 20005003	A	20000301
US 20020061841	AA	20020523	US 944564	A	20010904
WO 200051580	A2	20000908	WO 2000IB222	A	20000302
WO 200051580	A3	20011018	WO 2000IB222	A	20000302

Priority Data (No,Kind,Date):

GB 994777 A 19990302  
 GB 9913341 A 19990608  
 WO 2000IB222 W 20000302  
 GB 998034 A 19990408

2/AB/3 (Item 1 from file: 351)  
 DIALOG(R)File 351:Derwent WPI  
 (c) 2003 Thomson Derwent. All rts. reserv.

013415300

WPI Acc No: 2000-587238/200055

XRAM Acc No: C00-175070

Use of glycoposphopeptical or pure Nigella sativa seeds to treat or prevent asthma and allergies or to treat or prevent diseases in which the body defense mechanism is cell mediated immunity e.g. influenza

Patent Assignee: AL-JASSIM R (ALJA-I); AL-KAISI B (ALKA-I); JAMES D (JAME-I); NASSIEF N A (NASS-I)

Inventor: NASSIEF N A

Number of Countries: 091 Number of Patents: 005

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200051580	A2	20000908	WO 2000IB222	A	20000302	200055 B
GB 2348132	A	20000927	GB 20005003	A	20000301	200055
AU 200031829	A	20000921	AU 200031829	A	20000302	200065

US 20020061841 A1 20020523 US 2001944564 A 20010904 200239  
 EP 1242102 A2 20020925 EP 2000909548 A 20000302 200271  
 WO 2000IB222 A 20000302

Priority Applications (No Type Date): GB 9913341 A 19990608; GB 994777 A 19990302

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200051580 A2 E 28 A61K-031/00

Designated States (National): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN  
 CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP  
 KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE  
 SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR  
 IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW

GB 2348132 A A61K-035/78

AU 200031829 A A61K-031/00 Based on patent WO 200051580

US 20020061841 A1 A61K-035/78

EP 1242102 A2 E A61K-035/78 Based on patent WO 200051580

Designated States (Regional): AT BE CH CY DE DK ES FI FR GB GR IE IT LI  
 LU MC NL PT SE

Abstract (Basic): WO 200051580 A2

Abstract (Basic):

NOVELTY - Glycophosphopeptical (i.e. a glucomannan form *Candida utilis*) is administered to mammals, especially humans, to treat or prevent asthma and allergies.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) use of an agent (I) prepared from pure *Nigella sativa* seeds having the same function as glycophosphopeptical to treat/prevent asthma and allergies as above;

(2) administering glycophosphopeptical to treat diseases caused by type I IgE-mediated hypersensitivity reactions or to treat/prevent diseases in which the body defense mechanism is cell mediated immunity; and

(3) kits to diagnose allergy / asthma and its severity, using measurements of serum interferon concentration.

ACTIVITY - Antiinflammatory; antiallergic; antiasthmatic; dermatological ; immunostimulant. Glycophosphopeptical selectively switched off eosinophilic inflammation e.g. 55 asthma patients treated with glycophosphopeptical demonstrated a significant decrease in eosinophils in sputum (% of inflammatory cells) from 80 % to 10 % in two weeks.

MECHANISM OF ACTION - Th1 lymphocyte stimulator.

Glycophosphopeptical or *N. sativa* extract stimulated T lymphocyte activation and proliferation in culture comparable to purified protein derivative of *Bacillus Calmette Guerin* (BCG), a standard agent stimulating cell mediated immunity (claimed).

USE - Glycophosphopeptical can be used in asthma / allergy drugs e.g. to treat extrinsic/intrinsic/mixed asthma , allergic and perennial rhinitis , allergic conjunctivitis , chronic urticaria , atopic dermatitis or laryngeal oedema (claimed). It can be included as a Th1 lymphocyte stimulating agent (optionally with an excipient) in pharmaceutical compositions (claimed) and used as a short-term therapy (5-20 days and preferably 5 days) to treat patients with chronic disease to obtain long-term clinical remission (i.e. of months), as a result of selective switching-off of eosinophilic inflammation (claimed). Glycophosphopeptical or (I) is also useful to treat other diseases caused by type I IgE-mediated hypersensitivity reactions and to treat/prevent diseases in which the body defense mechanism is cell mediated immunity e.g. viral infections (e.g. influenza and common cold), urinary tract infections, pelvic inflammatory diseases (e.g.

neuroimmune appendicitis), cancer, Crohn's disease and facial palsy (all claimed). Treatment of diseases caused by type I IgE-mediated hypersensitivity reaction using glycoposphopeptical or (I) is claimed to depend on the fact that interferon is an in vivo Eosinophilic Chemotactic Factor, and that serum interferon and T-helper type 1 (Th1) lymphocytes control the pre-inflammatory phase of allergic reaction.

pp; 28 DwgNo 0/0